

Special Issue on
The Targeting Medication of PPARs on Human Diseases

CALL FOR PAPERS

Peroxisome proliferators-activated receptors (PPARs) are a subfamily of ligand inducible nuclear hormone receptors with distinct tissue distribution and functions. All three PPAR isotypes, PPAR α , PPAR β/δ , and PPAR γ , are activated by a variety of molecules and regulate a spectrum of genes involved in development, lipid and carbohydrate metabolism, inflammation, and proliferation and differentiation of many cell types in different tissues. Many types of medicine exert multiple effects targeted for PPARs in various human diseases, including metabolic disorders, immune injury, inflammation, and tumors with increasing benefits. Given that PPARs are known to play a role in human diseases, the targeted medication of PPARs needs to be developed for appropriate clinical utilization.

We invite investigators to submit original research articles and review articles that aim to increase the knowledge regarding the related medicines targeted for PPARs signaling pathway at different organ levels. These medicines take PPARs as the specific target with remarkable curative effect and limited side effect. Studies describing basis function and pathogenesis of PPARs in diseases are also solicited.

Potential topics include but are not limited to the following:

- ▶ Medicines targeted for PPARs on human diseases, including obesity, type 2 diabetes, cardiovascular diseases, inflammation, hepatic steatosis, and certain cancers
- ▶ Pharmacological and toxicological effects of PPARs-related medicines
- ▶ The combined drug therapy for PPARs signaling pathway
- ▶ The drug screening of PPARs inhibitors as novel targeting agents
- ▶ The comparison of PPAR targeted medicines with other targeted drugs
- ▶ The interplay between PPAR signaling pathway and other pathways in pharmacotherapeutics

Authors can submit their manuscripts through the Manuscript Tracking System at <https://mts.hindawi.com/submit/journals/ppar/tmphd/>.

Papers are published upon acceptance, regardless of the Special Issue publication date.

Lead Guest Editor

Chuanyong Guo, Tongji University,
Shanghai, China
guochuanyong@hotmail.com

Guest Editors

Yingzi Cong, University of Texas
Medical Branch, Galveston, USA
yicong@utmb.edu

Jiahua Wang, University of Sydney,
Sydney, Australia
jianhua.wang@sydney.edu.au

Yuewen Gong, University of Manitoba,
Winnipeg, Canada
yuewen.gong@umanitoba.ca

Ling Xu, Shanghai Jiao Tong University,
Shanghai, China
xiaoling05@126.com

Xiaoming Fan, Fudan University,
Shanghai, China
xiaomingfan57@hotmail.com

Submission Deadline

Friday, 11 August 2017

Publication Date

December 2017